Matinas BioPharma concludes BioNTech mRNA collaboration, plans Phase 3 trial for MAT2203 antifungal

Matinas BioPharma Holdings, Inc.

BioNTech oral mRNA collaboration ended; in vivo oral study showed no activity, but systemic delivery and stability demonstrated.
Company plans to submit revised Phase 3 trial design for MAT2203 in aspergillosis and other IFIs in Q2 2023.
Seven patients with IFIs treated under compassionate use; oral MAT2203 showed safety and efficacy in diverse infections.
Cash position sufficient to fund operations into second half of 2024.
Expanded collaboration with National Resilience for mRNA/oligonucleotide delivery; initial data expected Q3 2023.

item 2.02 item 7.01 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Matinas BioPharma Holdings, Inc. reported financial results for the quarter ended March 31, 2023.

Period: the quarter ended March 31, 2023
Result: reported results

Exact text from the filing

On May 10, 2023, Matinas BioPharma Holdings, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended March 31, 2023.

View on SEC.gov

3 earnings releases filed in the last 30 days. Browse all earnings releases →

Matinas BioPharma Holdings, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-23-016160

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.